Welcome to our dedicated page for Aptargroup news (Ticker: ATR), a resource for investors and traders seeking the latest updates and insights on Aptargroup stock.
AptarGroup, Inc. (NYSE: ATR) generates news across drug delivery, digital health and consumer dispensing technologies. As a global company serving pharmaceutical, beauty, food, beverage, personal care and home care markets, its announcements often highlight new delivery systems, clinical collaborations, acquisitions and financial updates that are relevant to investors and industry observers.
Recent news has featured Aptar Pharma’s nasal and ophthalmic platforms, such as LuerVax and Spray Divider being used in a Phase II clinical trial of an intranasal COVID-19 vaccine candidate, and Bidose liquid nasal spray systems delivering an FDA-approved treatment for paroxysmal supraventricular tachycardia. The company also reports on developments in eye care, including its Beat the Blink technology and preservative-free multidose dispensers, as well as broader portfolios of ophthalmic solutions.
Aptar’s Digital Health division appears frequently in updates related to connected health tools and data-driven care. Examples include the integration of the Migraine Buddy app with biometric data from wearable devices and FDA 510(k) clearance for HeroTracker Sense, a connected add-on for metered-dose inhalers within a respiratory disease management platform.
Investors following ATR news will also find earnings releases, segment performance commentary, conference participation announcements and information on capital markets activity, such as senior notes offerings. This news page brings together these items so readers can review Aptar’s latest product milestones, partnerships, digital health initiatives and financial communications in one place.
AptarGroup, Inc. (NYSE:ATR) reported an 8% increase in first-quarter 2021 sales, totaling $777 million. Core sales rose 1%, driven by strong demand in the Food + Beverage segment. Reported earnings per share jumped 48% to $1.24, boosted by a non-cash gain of $0.19 per share from an equity investment. Adjusted earnings per share increased 10% to $1.09. The company expects second-quarter EPS guidance between $0.91 to $0.99, reflecting ongoing challenges in prescription drug markets but optimistic long-term growth potential. A quarterly dividend was increased by 6% to $0.38 per share.
AptarGroup, Inc. (NYSE: ATR) has declared a quarterly cash dividend of $0.38 per share, representing a 6% increase from the previous dividend. The payment date is May 19, 2021, for stockholders of record as of April 28, 2021. In 2020, Aptar returned $93 million to shareholders and is set for its 28th consecutive year of increased annual dividends. The company achieved a Total Shareholder Return of 102% over the past five years, outperforming its peer group and the S&P Midcap 400.
Summary not available.
AptarGroup, Inc. (NYSE:ATR) reported strong fourth quarter results with reported sales growing 12% to $749 million. Core sales increased 5%, driven by demand in Pharma and Food & Beverage segments. Earnings per share rose 8% to $0.79. For the year, reported sales grew 2% to $2.93 billion, but earnings per share fell 12% to $3.21 due to pandemic impacts. The company achieved record cash flow from operations of $570 million and declared a quarterly dividend of $0.36 per share, highlighting its commitment to shareholders.
AptarGroup (NYSE: ATR) announces a partnership with CARE® to support global health initiatives, including the Fast + Fair COVID-19 Vaccine Response Campaign. This initiative aims to ensure equitable vaccine access for over 100 million people, focusing on women, impoverished communities, and healthcare workers across 10 countries. Aptar’s sponsorship emphasizes its commitment to diversity, inclusion, and women's empowerment, while aligning with its business model of producing vaccine delivery components. The collaboration promises to enhance CARE's efforts in advocating for equitable health policies worldwide.
AptarGroup, Inc. (NYSE: ATR) has announced that its Activ-Film™ technology will protect a new SARS Rapid Antigen test for COVID-19, recently granted Emergency Use Authorization (EUA) by the FDA. This QuickVue® SARS Antigen test, developed by Quidel® Corporation, delivers results in just 10 minutes, enhancing access to affordable COVID-19 testing, especially in schools and rural areas. Activ-Film™ integrates material science to ensure test accuracy by protecting against moisture and environmental factors. Aptar is dedicated to providing critical healthcare solutions during the pandemic.
AptarGroup, Inc. (NYSE: ATR) has declared a quarterly cash dividend of $0.36 per share, payable on February 17, 2021, to stockholders of record as of January 27, 2021. The company will also hold a conference call on February 19, 2021, at 8:00 a.m. Central Time to discuss its fourth quarter and year-end results for 2020. Additionally, the 2021 Annual Meeting of Stockholders will be held virtually on May 5, 2021, at 9:00 a.m. Central Time, with a record date for voting set for March 12, 2021.
AptarGroup, Inc. (NYSE: ATR) will participate in the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, with a virtual presentation at 2:50 p.m. (EST) by key executives including President and CEO Stephan Tanda. A live webcast will be available in the Investors section of the Aptar website and a replay will be accessible for 90 days post-event. Aptar is a global leader in drug delivery and packaging solutions, headquartered in Crystal Lake, Illinois, employing 14,000 people across 19 countries.
AptarGroup, Inc. (NYSE: ATR) has announced the schedule for its quarterly conference calls for 2021. Key dates include:
- 4th Quarter and Annual Results: February 18, 2021 (Call on February 19, 2021, at 8:00 a.m. CT)
- 1st Quarter 2021 Results: April 29, 2021 (Call on April 30, 2021, at 8:00 a.m. CT)
- 2nd Quarter 2021 Results: July 29, 2021 (Call on July 30, 2021, at 8:00 a.m. CT)
- 3rd Quarter 2021 Results: October 28, 2021 (Call on October 29, 2021, at 8:00 a.m. CT)
Press releases will be issued after the close of trading on NYSE.
Summary not available.